Anti-p53 Antibodies and p53 Protein Expression in Cholangiocarcinoma

Hepato-Gastroenterology

Volumn 51, Issue 55, 2004, Pages 25-28

  Limpaiboon, Temduang ^a   Sripa, Banchob ^b   Wongkham, Sopit ^b   Bhudhisawasdi, Vajarabhongsa ^b   Chau in, Siri ^b   Teerajetgul, Yaovalak ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Anti p53 antibodies; Biliary tract cancer; Cholangiocarcinoma; p53 gene; p53 protein expression

Indexed keywords

PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BILE DUCT CARCINOMA; BIOACCUMULATION; CANCER STAGING; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSTRUMENTATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX; STATISTICAL SIGNIFICANCE; TUMOR LOCALIZATION;

ADULT; AGED; ANTIBODIES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744232208     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342:705-708.
2. Hollstien M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancers. Science 1991; 253:49-53.
3. Soussi T, Caron de Fromentel C, May P: Structural aspects of the p53 protein in relation to gene evolution. Oncogene 1990; 5:945-952.
4. Porter PL, Gown AM, Kramp SG, Coltrera MD: Widespread p53 overexpression in human malignant tumours. Am J Pathol 1992; 140:145-153.
5. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30:403-408.
6. Angelopoulou K, Stratis M, Diamandis EP: Humoral immune response against p53 protein in patients with colorectal carcinoma. Cancer 1997; 70:46-51.
7. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma correlation with clinicopathological features and survival. Cancer 1996; 78:2146-2152.
8. Maehara Y, Kakeji Y, Watanabe A, et al: Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma. Cancer 1999; 85:302-308.
9. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, et al: Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995; 36:455-458.
10. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994; 69:809-816.
11. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994; 69:1115-1119.
12. Wild CP, Ridanpaa M, Anttila S, et al: p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer 1995; 64:176-181.
13. Hammel P, Boissier B, Chaumette MT, et al: Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997; 40:356-361.
14. Rainov NG, Dobberstein KU, Fittkau M, et al: Absence of p53 autoantibodies in sera from glioma patients. Clin Cancer Res 1995; 1:775-781.
15. Vatanasapt V, Uttaravichien T, Mairiang E, Pairojkul C, Chartbanchachai V, Haswell-Elkins MR: Northeast Thailand: a region with a high incidence of cholangiocarcinoma. Lancet 1990; 1:116-117.
16. Parkin DM, Whelan SL, Ferley J, Raymon L, Young J (Eds.): Cancer incidence in five continents. Vol VII. Lyon: IARC Scientific Publications, 1997; pp. 438-441.
17. Vatanasapt V, Martin N, Sriplung H, et al: Cancer incidence in Thailand, 1988-1991. Cancer Epidemiol Biomarkers Prev 1995; 4:475-483.
18. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S: Effects of dimethynitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 1978; 38:4634-4639.
19. Flavel DJ: Liver-fluke infection as an aetiological factor in bile-duct carcinoma of man. Trans R Soc Trop Med Hyg 1981; 75:841-843.
20. Haswell-Elkins MR, Satarug S, Elkins DB: Opisthorchis viverrini infection in Northeast Thailand and its relationship to cholangiocarcinoma. J Gastroenterol Hepatol 1992; 7:538-548.
21. Haswell-Elkins MR, Satarug S, Tsuda M, et al: Liver fluke infection and cholagiocarcinoma: model of endogenous nitric oxide and extrahepatic nitrosation in human carcinogenesis. Mutat Res 1994; 305:241-252.
22. Uttaravichen T, Buddhiswasdi V, Pairojkul C: Bile duct cancer and liver fluke: pathology, presentation and surgical management. Asian J Surgery 1996; 19:267-270.
23. Kiba T, Tsuda H, Pairojkul C, Inoue S, Sugimura T, Hirohashi S: Mutations of the p53 tumor suppressor gene and the ras gene family in intrahepatic cholangiocellular carcinomas in Japan and Thailand. Mol Carcinog 1993; 8:312-318.
24. Ohashi K, Nakajima Y, Kanehiro H, et al: Ki-ras mutations and p53 protein expressions in intrahepatic cholangiocarcinomas: relation to gross tumor morphology. Gastroenterol 1995; 109:1612-1617.
25. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:577-580.
26. Shi SR, Chaiwun B, Young L, Cote RJ, Taylor CR: Antigen retrieval technique utilizing citrate buffer or urea solution for immunohistochemical demonstration of androgen receptor in formalin-fixed paraffin sections. J Histochem Cytochem 1993; 41:1599-1604.
27. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B: Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57:1-9.
28. Lubin R, Schlichtholz B, Bengoufa D, et al: Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993; 53:5872-5876.
29. Angelopoulou K, Diamandis EP, Sutherland DJ, Kellen JA, Bunting PS: Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58:480-487.
30. Davidoff AM, Iglehart JD, Marks JR: Immune response to p53 is dependent upon HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992; 89:3439-3442.
31. Kaur J, Srivastava A, Ralhan R: Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer 1997; 74:609-613.
32. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52:4168-4174.
33. Lubin R, Zalcman G, Bouchet L, et al: Serum p53 antibodies as early markers of lung cancer. Nature Med 1995; 1:701-702.